Joel Dudley is a physician-scientist turned venture investor who brings hands-on experience building precision medicine infrastructure at Mount Sinai and Tempus to his role as biotech partner at Innovation Endeavors. He focuses on backing companies that treat biology as an engineering problem and applies AI to specific regulatory bottlenecks in drug development, such as his investment in Weave Bio for automating regulatory document processes.

• Active investor in the life sciences and biotech sectors with a specific focus on drug discovery and development tools. Highlighted recent lead investments in companies like Weave Bio for regulatory reporting and Harmonic Discovery for therapeutics.
• A thesis centered on the convergence of computational methods and biology. Shared excitement about Think Biosciences for merging computational biology with biological computation and discussed these topics on the BIOS community podcast to explain how data builds new solutions in the field.
• Strong preferences regarding Large Language Models and AI tools. Criticized Google Gemini for being too restrictive compared to alternatives like Claude or Grok, and emphasized the importance of uncensored models.
• Interest in the philosophy of science and knowledge. Posted a custom license plate paying homage to physicist David Deutsch and references concepts like the preservation of means of error correction.
• Support for clean energy innovation. Expressed a desire to see clean elemental energy initiatives brought to Colorado, citing progress made in Georgia as a positive example.
• Fan of the Green Bay Packers and NFL football. Frequently comments on game specifics, such as play calling by Matt LaFleur or the performance of Aaron Jones at AT&T stadium.